We found that the delivery of CMV70-3P inhibitor significantly inhibited SOX2 expression in U118CMV infected and GBM13 glioma stem cells (p < 0.029 and 0.008, respectively Figure 3F and 3G) without altering the expressions of CD133, NESTIN and OLIG2. This evidence concerns the gene SOX2 and central nervous system cancer.